BeiGene (Germany) Performance
| 49BA Stock | EUR 296.00 6.00 2.07% |
BeiGene has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0127, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning BeiGene are expected to decrease at a much lower rate. During the bear market, BeiGene is likely to outperform the market. BeiGene right now shows a risk of 2.33%. Please confirm BeiGene mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to decide if BeiGene will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BeiGene are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable fundamental drivers, BeiGene is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
1 | Morgan Stanley Sticks to Their Buy Rating for BeiGene Ltd - The Globe and Mail | 11/10/2025 |
2 | What valuation multiples suggest for BeiGene Ltd. Depositary Receipt stock - Quarterly Performance Summary Verified Stock Trade Ideas - newser.com | 11/19/2025 |
3 | Guggenheim Maintains BeiGene With Buy Rating, Maintains Target Price 400 - | 12/10/2025 |
4 | BeOne Medicines Ltd. grants 21,274 RSUs to employees - MSN | 12/29/2025 |
5 | BeiGene received an increase of 1,480,200 ordinary shares by JPMorgan, valued at approximately HKD 305 million. - | 01/21/2026 |
6 | Early Trading Movement BeiGene Rises Over 4 percent as NHC Launches New Pricing Mechanism for Innovative Drugs - | 02/02/2026 |
BeiGene |
BeiGene Relative Risk vs. Return Landscape
If you would invest 28,400 in BeiGene on November 8, 2025 and sell it today you would earn a total of 1,200 from holding BeiGene or generate 4.23% return on investment over 90 days. BeiGene is generating 0.0965% of daily returns assuming 2.3319% volatility of returns over the 90 days investment horizon. Simply put, 20% of all stocks have less volatile historical return distribution than BeiGene, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BeiGene Target Price Odds to finish over Current Price
The tendency of BeiGene Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 296.00 | 90 days | 296.00 | about 19.13 |
Based on a normal probability distribution, the odds of BeiGene to move above the current price in 90 days from now is about 19.13 (This BeiGene probability density function shows the probability of BeiGene Stock to fall within a particular range of prices over 90 days) .
BeiGene Price Density |
| Price |
Predictive Modules for BeiGene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BeiGene. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BeiGene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BeiGene is not an exception. The market had few large corrections towards the BeiGene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BeiGene, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BeiGene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | -0.01 | |
σ | Overall volatility | 15.23 | |
Ir | Information ratio | 0.05 |
BeiGene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BeiGene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BeiGene can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 3.81 B. Net Loss for the year was (644.79 M) with profit before overhead, payroll, taxes, and interest of 4.29 B. | |
| BeiGene has accumulated about 1.54 B in cash with (140.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.49. | |
| Roughly 17.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Early Trading Movement BeiGene Rises Over 4 percent as NHC Launches New Pricing Mechanism for Innovative Drugs - |
BeiGene Fundamentals Growth
BeiGene Stock prices reflect investors' perceptions of the future prospects and financial health of BeiGene, and BeiGene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BeiGene Stock performance.
| Return On Equity | 0.0181 | ||||
| Return On Asset | 0.0169 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 31.68 B | ||||
| Shares Outstanding | 101.81 M | ||||
| Price To Book | 9.18 X | ||||
| Price To Sales | 6.59 X | ||||
| Revenue | 3.81 B | ||||
| Gross Profit | 4.29 B | ||||
| EBITDA | 328.17 M | ||||
| Net Income | (644.79 M) | ||||
| Cash And Equivalents | 1.54 B | ||||
| Cash Per Share | 25.49 X | ||||
| Total Debt | 851.53 M | ||||
| Debt To Equity | 17.50 % | ||||
| Book Value Per Share | 31.63 X | ||||
| Cash Flow From Operations | (140.63 M) | ||||
| Earnings Per Share | 0.44 X | ||||
| Total Asset | 5.92 B | ||||
| Retained Earnings | (8.61 B) | ||||
About BeiGene Performance
By analyzing BeiGene's fundamental ratios, stakeholders can gain valuable insights into BeiGene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BeiGene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BeiGene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the Peoples Republic of China, the United States, and internationally. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the Peoples Republic of China. BEIGENE LTD is traded on Frankfurt Stock Exchange in Germany.Things to note about BeiGene performance evaluation
Checking the ongoing alerts about BeiGene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BeiGene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 3.81 B. Net Loss for the year was (644.79 M) with profit before overhead, payroll, taxes, and interest of 4.29 B. | |
| BeiGene has accumulated about 1.54 B in cash with (140.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.49. | |
| Roughly 17.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Early Trading Movement BeiGene Rises Over 4 percent as NHC Launches New Pricing Mechanism for Innovative Drugs - |
- Analyzing BeiGene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BeiGene's stock is overvalued or undervalued compared to its peers.
- Examining BeiGene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BeiGene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BeiGene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BeiGene's stock. These opinions can provide insight into BeiGene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |